Will Life Sciences Follow Suit?

Arash of globalization is transferring upscale jobs offshore. This is the politically charged business practice of sending high-paying jobs out of the United States and Western Europe to Eastern Europe and developing countries, where salaries are considerably lower.For us, there are two questions: Will life sciences research, industrial or academic, follow this offshore trend? And if so, who will be the winners and the losers?The life sciences have so far been pretty deaf to the siren song of ou

Written byRichard Gallagher
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Arash of globalization is transferring upscale jobs offshore. This is the politically charged business practice of sending high-paying jobs out of the United States and Western Europe to Eastern Europe and developing countries, where salaries are considerably lower.

For us, there are two questions: Will life sciences research, industrial or academic, follow this offshore trend? And if so, who will be the winners and the losers?

The life sciences have so far been pretty deaf to the siren song of outsourcing. In the United States and Western Europe, leaders in the political and scientific communities argue that the combination of human and intellectual capital, the quality of support and infrastructure, and the access to wealthy markets make it unthinkable that the life sciences community would join the offshore boom.

But consider other professions: Chip-design teams, engineering firms, software development companies, and financial analysis offices, among others, are leaving to employ ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies